Ranbaxy Announces Improved Business Standards and Quality Assurance InitiativesMay 22, 2013
TOKYO, May 22 /Kyodo JBN-AsiaNet –
Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary of Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo), announced on May 22 the actions that Ranbaxy has taken in recent years to address past conduct under prior management (http://www.daiichisankyo.com/media_investors/media_relations/press_releases/index.html).
Daiichi Sankyo continues to support Ranbaxy in its efforts to address and correct the conduct of the past which led to the investigations by the U.S. Department of Justice (“DOJ”) and the U.S. Food and Drug Administration (“USFDA”). These efforts include significant changes to Ranbaxy’s management, culture, operations and compliance.
Daiichi Sankyo believes that certain former shareholders of Ranbaxy concealed and misrepresented critical information concerning the U.S. DOJ and FDA investigations. Daiichi Sankyo is currently pursuing its available legal remedies and cannot comment further on the subject at this time.
About Daiichi Sankyo Co., Ltd.
Listed: Code No.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges President and CEO: Joji Nakayama
Source: Daiichi Sankyo Co., Ltd.
Corporate Officer & Vice President
Corporate Communications Department
Daiichi Sankyo Co., Ltd.